Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Purchases $2,000,000.60 in Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Invus Global Management, Llc acquired 1,538,462 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was acquired at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the purchase, the director directly owned 1,538,462 shares in the company, valued at approximately $2,000,000.60. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Lexicon Pharmaceuticals Stock Up 4.2%

Shares of NASDAQ:LXRX opened at $1.23 on Friday. The company has a market cap of $447.07 million, a price-to-earnings ratio of -6.47 and a beta of 0.98. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $1.83. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The company has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.28.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $14.18 million for the quarter, compared to analysts’ expectations of $5.81 million. Lexicon Pharmaceuticals had a negative return on equity of 52.90% and a negative net margin of 96.77%. As a group, equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $26,000. R Squared Ltd bought a new position in Lexicon Pharmaceuticals in the second quarter worth approximately $28,000. Leonteq Securities AG purchased a new position in Lexicon Pharmaceuticals during the 4th quarter worth $34,000. Vermillion & White Wealth Management Group LLC raised its position in Lexicon Pharmaceuticals by 400.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 26,000 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth $51,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on LXRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.23.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.